目的 探討c-met mRNA在乳腺癌患者術(shù)后腋窩引流液中表達的意義。
方法 用RT-PCR法檢測乳腺癌患者術(shù)后腋窩引流液中c-met mRNA的表達,分析其表達與腫瘤大小、腋窩淋巴結(jié)轉(zhuǎn)移、雌激素受體(estrogen receptor,ER)、孕激素受體(progesterone receptor,PR)及生長因子受體2(c-erbB-2)的關(guān)系,以及5-FU加蒸餾水沖洗手術(shù)野對c-met mRNA表達的影響。
結(jié)果 ?、賑-met mRNA能在乳腺癌術(shù)后腋窩引流液中表達,其陽性率高于病理檢查腋窩淋巴結(jié)轉(zhuǎn)移的陽性率(P<0.05)。②腋窩淋巴結(jié)轉(zhuǎn)移、腫瘤大小與c-met mRNA的表達有關(guān)。③腫瘤ER、PR 及c-erbB-2的表達與c-met mRNA的表達無關(guān)。④5-FU加蒸餾水沖洗手術(shù)創(chuàng)面能明顯降低c-met mRNA的表達。
結(jié)論 c-met mRNA是乳腺癌微轉(zhuǎn)移研究的理想特異性標志物,與常規(guī)病理檢查腋窩淋巴結(jié)相比,RT-PCR檢測腋窩引流液中c-met mRNA的表達能更早檢測出腫瘤細胞在胸壁淋巴管中的轉(zhuǎn)移,并具有更高的準確性。
引用本文: 楊衛(wèi)軍,黃志剛,李春來,吳正陽,尹家俊. c-met mRNA在乳腺癌術(shù)后腋窩引流液中表達的意義. 中國普外基礎(chǔ)與臨床雜志, 2007, 14(3): 259-262. doi: 復(fù)制
版權(quán)信息: ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有,未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
1. | 傅西林, 張立華, 張國珩. 常規(guī)檢查淋巴結(jié)轉(zhuǎn)移陰性之乳腺癌腋窩組織再連續(xù)切片檢查的研究 [J]. 中國腫瘤臨床, 1985; 12(1)∶20. |
2. | 陳朝倫, 盧曉梅, 黃絨, 等. Ⅰ期癌癥患者切除淋巴結(jié)內(nèi)隱匿性微小轉(zhuǎn)移癌灶的檢查及其臨床病理意義 [J]. 中華腫瘤雜志, 1997; 19(1)∶69. |
3. | Gardner B, Feldman J. Are positive axillary nodes in breast ca-ncer markers for incurable disease? [J]. Ann Surg, 1993; 218(3)∶270. |
4. | Noguchi M. Sentinel lymph node biopsy and breast cancer [J]. Br J Surg, 2002; 89(1)∶21. |
5. | 張維銘. 現(xiàn)代分子生物學(xué)實驗手冊 [M]. 北京: 科學(xué)出版社, 2003∶103~106. |
6. | Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model [J]. Cancer Res, 2001; 61(20)∶7518. |
7. | Kermorgant S, Aparicio T, Dessirier V, et al. Hepatocyte gr-owth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement [J]. Carcinogenesis, 2001; 22(7)∶1035. |
8. | Wang Y, Selden AC, Morgan N, et al. Hepatocyte growth factor/scatter factor expression in human mammary epithelium [J]. Am J Pathol, 1994; 144(4)∶675. |
9. | Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer [J]. Cancer Res, 1994; 54(7)∶1630. |
10. | Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues [J]. Oncogene, 1991; 6(11)∶1997. |
11. | Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer [J]. Biochem Biophys Res Commun, 1992; 189(1)∶227. |
12. | Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas [J]. Oncogene, 1992; 7(12)∶2549. |
13. | Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas [J]. Oncogene, 1992; 7(1)∶181. |
14. | 陳顯玉, 喻梅英, 楊竹林, 等. 乳腺良惡性病變組織c-met蛋白和轉(zhuǎn)化生長因子α的表達及意義 [J]. 中國普外基礎(chǔ)與臨床雜志, 1999; 6(2)∶81. |
15. | 尹家俊, 宋燕. 肝細胞生長因子及受體c-met在乳腺癌中的研究進展 [J]. 中國普外基礎(chǔ)與臨床雜志, 2000; 7(5)∶347. |
16. | Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, et al. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors [J]. Cancer, 2003; 97(8)∶1841. |
17. | Tsarfaty I, Alvord WG, Resau JH, et al. Alteration of Met protooncogene product expression and prognosis in breast carcinomas [J]. Anal Quant Cytol Histol, 1999; 21(5)∶397. |
18. | Ghoussoub RA, Dillon DA, D’Aquila T, et al. Expression of c-met is a strong independent prognostic factor in breast carcinoma [J]. Cancer, 1998; 82(8)∶1513. |
19. | 徐叔云主編. 中華臨床藥物學(xué) [M]. 北京: 人民衛(wèi)生出版社, 2003∶1429. |
20. | Scorilas A, Yotis J, Stravolemos K, et al. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients [J]. Anticancer Res, 1995; 15(4)∶1543. |
- 1. 傅西林, 張立華, 張國珩. 常規(guī)檢查淋巴結(jié)轉(zhuǎn)移陰性之乳腺癌腋窩組織再連續(xù)切片檢查的研究 [J]. 中國腫瘤臨床, 1985; 12(1)∶20.
- 2. 陳朝倫, 盧曉梅, 黃絨, 等. Ⅰ期癌癥患者切除淋巴結(jié)內(nèi)隱匿性微小轉(zhuǎn)移癌灶的檢查及其臨床病理意義 [J]. 中華腫瘤雜志, 1997; 19(1)∶69.
- 3. Gardner B, Feldman J. Are positive axillary nodes in breast ca-ncer markers for incurable disease? [J]. Ann Surg, 1993; 218(3)∶270.
- 4. Noguchi M. Sentinel lymph node biopsy and breast cancer [J]. Br J Surg, 2002; 89(1)∶21.
- 5. 張維銘. 現(xiàn)代分子生物學(xué)實驗手冊 [M]. 北京: 科學(xué)出版社, 2003∶103~106.
- 6. Tomioka D, Maehara N, Kuba K, et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model [J]. Cancer Res, 2001; 61(20)∶7518.
- 7. Kermorgant S, Aparicio T, Dessirier V, et al. Hepatocyte gr-owth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement [J]. Carcinogenesis, 2001; 22(7)∶1035.
- 8. Wang Y, Selden AC, Morgan N, et al. Hepatocyte growth factor/scatter factor expression in human mammary epithelium [J]. Am J Pathol, 1994; 144(4)∶675.
- 9. Yamashita J, Ogawa M, Yamashita S, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer [J]. Cancer Res, 1994; 54(7)∶1630.
- 10. Di Renzo MF, Narsimhan RP, Olivero M, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues [J]. Oncogene, 1991; 6(11)∶1997.
- 11. Kuniyasu H, Yasui W, Kitadai Y, et al. Frequent amplification of the c-met gene in scirrhous type stomach cancer [J]. Biochem Biophys Res Commun, 1992; 189(1)∶227.
- 12. Di Renzo MF, Olivero M, Ferro S, et al. Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas [J]. Oncogene, 1992; 7(12)∶2549.
- 13. Liu C, Park M, Tsao MS. Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas [J]. Oncogene, 1992; 7(1)∶181.
- 14. 陳顯玉, 喻梅英, 楊竹林, 等. 乳腺良惡性病變組織c-met蛋白和轉(zhuǎn)化生長因子α的表達及意義 [J]. 中國普外基礎(chǔ)與臨床雜志, 1999; 6(2)∶81.
- 15. 尹家俊, 宋燕. 肝細胞生長因子及受體c-met在乳腺癌中的研究進展 [J]. 中國普外基礎(chǔ)與臨床雜志, 2000; 7(5)∶347.
- 16. Tolgay Ocal I, Dolled-Filhart M, D’Aquila TG, et al. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors [J]. Cancer, 2003; 97(8)∶1841.
- 17. Tsarfaty I, Alvord WG, Resau JH, et al. Alteration of Met protooncogene product expression and prognosis in breast carcinomas [J]. Anal Quant Cytol Histol, 1999; 21(5)∶397.
- 18. Ghoussoub RA, Dillon DA, D’Aquila T, et al. Expression of c-met is a strong independent prognostic factor in breast carcinoma [J]. Cancer, 1998; 82(8)∶1513.
- 19. 徐叔云主編. 中華臨床藥物學(xué) [M]. 北京: 人民衛(wèi)生出版社, 2003∶1429.
- 20. Scorilas A, Yotis J, Stravolemos K, et al. c-erbB-2 overexpression may be used as an independent prognostic factor for breast cancer patients [J]. Anticancer Res, 1995; 15(4)∶1543.